News

According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent (DES) appeared to have similar outcomes to patients who received DAPT for a full year.

Home September 22, 2014
Home
U.S. CoreValve High Risk trial TCT 2014
Feature

According to a new study, transcatheter aortic valve replacement (TAVR) provided meaningful clinical benefits relative to surgical aortic valve replacement (SAVR) in high risk patients with incremental costs considered acceptable from a U.S. perspective.

Home September 19, 2014
Home
Study Blood Thinner Heart Attack Patients
Feature

The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in hospitals across the United States.

Home September 19, 2014
Home
X0000_Medtronic_Endeavor vessel healing illustration_0
Feature

September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug-eluting stent (DES) implantation demonstrated that six weeks of drug therapy was not superior to six months of therapy with regard to net clinical outcomes. ISAR-TRIPLE is the largest randomized trial to date investigating triple therapy after stenting and the first trial evaluating the duration of triple therapy. Findings were reported earlier this week at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Home September 19, 2014
Home
Heart attack patient in emergency room_from Physio-control PR photos
Feature

September 19, 2014 — According to a new study, peritoneal hypothermia is feasible for patients who have suffered ST-segment elevation myocardial infarction (STEMI). However, the procedure was associated with an increased rate of adverse events without reducing infarct size. These findings were reported at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium earlier this week.

Home September 19, 2014
Home
News

New data from a landmark clinical trial found that after five years, transcatheter aortic valve replacement (TAVR) demonstrated a persistent mortality benefit, improved functional status, and resulted in a lower rate of repeat hospitalizations when compared with standard therapy for patients with severe aortic stenosis who are not candidates for surgery.

Home September 18, 2014
Home
News

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The DKCRUSH-VI clinical trial is the first study to compare FFR-guided and angiography-guided stenting.

Home September 18, 2014
Home
ExoSeal vascular closure device
Feature

September 17, 2014 — A new clinical trial found that vascular closure devices (VCDs) are non-inferior to manual compression in patients undergoing transfemoral coronary angiography. The findings were reported at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) annual scientific sessions in Washington, D.C.

Home September 17, 2014
Home
Technology

September 17, 2014 — GE Healthcare announced it has installed its Cath Lab Efficiency Manager at Saint Luke’s Mid America Heart Institute in Kansas City, Mo. The solution is a new analytical tool that analyzes the performance of an interventional lab, providing hospitals with important data they can use to identify areas of improvement.

Home September 17, 2014
Home
News

Unexpected trips to the hospital are inconvenient and worrisome for anyone, but for congestive heart failure sufferers, they can be all too frequent.

Home September 17, 2014
Home
News

BioControl Medical announced that it has reached an important clinical trial milestone, reaching 480 randomized subjects — or 70 percent — of the planned 650 subjects with congestive heart failure (HF) in the INOVATE-HF (INcrease Of VAgal TonE in Heart Failure) trial of its CardioFit system, the first medical device designed to treat HF using neurostimulation.

Home September 17, 2014
Home
News

September 16, 2014 — A quarter of adults in the United States have two or more chronic medical conditions, as do more than two-thirds of seniors, yet there are few clinical practice guidelines for cardiologists that take such comorbid conditions and their treatment into consideration.

Home September 16, 2014
Home
News

September 16, 2014 — Advanced Accelerator Applications (AAA), an international specialist in molecular nuclear medicine, announced this week it has entered into an agreement with GE Healthcare in Italy to acquire its Italian FDG-PET imaging agent business (fluorodeoxyglucose positron emission tomography). This acquisition includes the license to market GE Healthcare’s SteriPET (FDG) imaging agent in Italy.

Home September 16, 2014
Home
News

Tryton Medical Inc. announced that the first patient in the United States has been enrolled in the Extended Access Registry, a single arm study of its Tryton Side Branch Stent.

Home September 16, 2014
Home
News

The Minneapolis Heart Institute Foundation (MHIF) announced its first implant of the Portico Re-sheathable Transcatheter Aortic Valve System, developed by St. Jude Medical.

Home September 16, 2014
Home
Subscribe Now